Therapeutic time window for ischemic stroke

Koji Abe

Research output: Contribution to journalArticlepeer-review


Neuroprotection is essential for therapy in acute stage of stroke. Both neurotrophic factors (NTFs) and free radical scavenger can be such neuroprotective reagents with inhibiting death signals and potentiating survival signals under cerebral ischemia. Edaravone, a free radical scavenger, is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan. Edaravone scavenges hydroxyl radicals both in hydrophilic and hydrophobic conditions, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Combination therapy of Edaravone with tPA greatly increased survival of stroke animals, reduced infarct size, and inhibited molecular markers of oxidative damage in lipid, protein and DNA. Use of Edaravone greatly reduced hemorrhagic transformation accompanied by tPA treatment, and may also extend therapeutic time window with tPA therapy for more than 3 hr in human stroke patients.

Original languageEnglish
Pages (from-to)1182-1184
Number of pages3
JournalClinical Neurology
Issue number11
Publication statusPublished - 2011


  • Edaravone
  • Hemorrhagic transformation
  • Neuroprotection
  • tPA

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Therapeutic time window for ischemic stroke'. Together they form a unique fingerprint.

Cite this